Consumer Driven Health Care

Costs for CAR T-cell therapies will be far higher than many have imagined, reaching $1 million or more per patient, according to leading cancer experts. The next CAR T-cell drug could be approved as soon as November.

Tom Marino, withdrew from consideration following reports that he pushed legislation making it harder for the government to combat the opioid crisis.

According to a study from the Task Force on Low-Value Care, health care consumers are sinking $25 billion a year on low-value procedures that are often not even needed.

The concept of patient advocacy isnt new, but current trends are shining a spotlight on the growing need for this critical service.

Drugmakers said in prepared remarks that insurers, pharmacy-benefit managers and hospitals, among others, keep a large chunk of the money Americans spend on medicine and dont pass on savings to patients.

An analysis of Medicare Fee-for-Service claims data shows a substantial shift in site of care for outpatient drug therapies from the physician office to the hospital outpatient setting from 2008 to 2015.